Dulaglutide (Trulicity) The Third Once-Weekly GLP-1 Agonist

摘要

Diabetes is a rapidly growing, non-discriminatory disease that affects people of all ages and ethnicities. It is estimated that 9.3% of the United States population has diabetes. This equates to 29.1 million Americans who have the condition, of which 8.1 million are undiagnosed.Pharmacological treatment of type-2 diabetes has changed dramatically over the past five years, with new classes and drugs becoming available. Many of the medications used in the treatment of type-2 diabetes can be used in combination with various other oral therapies to achieve better glycemic control. Some can be given once weekly, an option that provides an avenue to limit polypharmacy and noncompliance, which otherwise may not have been achieved with daily monotherapy.